CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 397 filers reported holding CRISPR THERAPEUTICS AG in Q4 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,210 | -27.3% | 269 | -10.0% | 0.00% | -50.0% |
| Q2 2023 | $16,786 | +24.1% | 299 | 0.0% | 0.00% | +100.0% |
| Q1 2023 | $13,524 | +6.0% | 299 | -4.8% | 0.00% | -50.0% |
| Q4 2022 | $12,764 | -52.7% | 314 | -24.2% | 0.00% | -50.0% |
| Q3 2022 | $27,000 | +8.0% | 414 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $25,000 | -3.8% | 414 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $26,000 | -18.8% | 414 | -1.9% | 0.00% | -20.0% |
| Q4 2021 | $32,000 | +6.7% | 422 | +55.7% | 0.01% | -16.7% |
| Q3 2021 | $30,000 | +76.5% | 271 | +160.6% | 0.01% | +50.0% |
| Q2 2021 | $17,000 | +30.8% | 104 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $13,000 | -7.1% | 104 | +16.9% | 0.00% | -20.0% |
| Q4 2020 | $14,000 | +600.0% | 89 | +206.9% | 0.01% | +400.0% |
| Q3 2020 | $2,000 | 0.0% | 29 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $2,000 | +100.0% | 29 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $1,000 | – | 29 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |